Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Kazuya Motomura und 47 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Fund of National Federation of Health Insurance Societies, National Cancer Center Research and Development Fund.
Abstract (Originalsprache)
Background
This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved.
Methods
We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL.
Results
The most used regimen (46.8%) for GBM in patients aged ≤74 years was ‘Surgery + radiotherapy concomitant with temozolomide’. This regimen’s total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, ‘Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy’ was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month).
Conclusions
Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan.
- JCOG Data Center/Operations Office, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
- Department of Neurosurgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Japan.
- Department of Neurosurgery, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Japan.
- Department of Neurosurgery, Graduate School of Medical Sciences, 1-1-1, Honjo, Chuo-ku, Kumamoto University, Kumamoto, Japan.
- Department of Neurosurgery, Yokohama City University, 3-9, Fukuura, Kanazawa, Yokohama, Japan.
ORCID-Profile: Kazuya Motomura, Keita Sasaki, Motoo Nagane, Makoto Ohno, Ryosuke Matsuda, Yoshiki Arakawa, Yoshitaka Narita
Förderung
- Research Fund of National Federation of Health Insurance Societies
- National Cancer Center Research and Development Fund
Zitieren
APA
Motomura, K., Sasaki, K., Sugii, N., Yamaguchi, S., Inoue, H., Oshima, A., Tanaka, K., Otani, Y., Shirahata, M., Shibahara, I., Nagane, M., Tsuzuki, S., Matsutani, T., Tsukamoto, Y., Kijima, N., Asano, K., Ohno, M., Inoue, A., Mineharu, Y., …, & Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG) (2024). Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae116
Vancouver
Motomura K, Sasaki K, Sugii N, Yamaguchi S, Inoue H, Oshima A, et al. Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae116
BibTeX
@article{Motomura2024,
author = {Motomura, Kazuya and Sasaki, Keita and Sugii, Narushi and Yamaguchi, Shigeru and Inoue, Hirotaka and Oshima, Akito and Tanaka, Kazuhiro and Otani, Yoshihiro and Shirahata, Mitsuaki and Shibahara, Ichiyo and Nagane, Motoo and Tsuzuki, Shunsuke and Matsutani, Tomoo and Tsukamoto, Yoshihiro and Kijima, Noriyuki and Asano, Kenichiro and Ohno, Makoto and Inoue, Akihiro and Mineharu, Yohei and Miyake, Keisuke and Mitobe, Yuta and Hanihara, Mitsuto and Kawanishi, Yu and Deguchi, Shoichi and Saito, Masato and Matsuda, Ryosuke and Ujifuku, Kenta and Arita, Hideyuki and Sato, Yuichi and Yamashita, Shinji and Yonezawa, Ushio and Yamaguchi, Junya and Momii, Yasutomo and Ogawa, Takahiro and Kambe, Atsushi and Ohba, Shigeo and Fukai, Junya and Saito, Norihiko and Kinoshita, Masashi and Sumi, Koichiro and Otani, Ryohei and Uzuka, Takeo and Takebe, Noriyoshi and Koizumi, Shinichiro and Saito, Ryuta and Arakawa, Yoshiki and Narita, Yoshitaka and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG), Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)},
title = {Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae116}
}
EUVIMED